These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28341751)

  • 1. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.
    Pitroda SP; Bao R; Andrade J; Weichselbaum RR; Connell PP
    Clin Cancer Res; 2017 Aug; 23(15):4493-4500. PubMed ID: 28341751
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.
    Pitroda SP; Pashtan IM; Logan HL; Budke B; Darga TE; Weichselbaum RR; Connell PP
    Sci Transl Med; 2014 Mar; 6(229):229ra42. PubMed ID: 24670686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
    Graeser M; McCarthy A; Lord CJ; Savage K; Hills M; Salter J; Orr N; Parton M; Smith IE; Reis-Filho JS; Dowsett M; Ashworth A; Turner NC
    Clin Cancer Res; 2010 Dec; 16(24):6159-68. PubMed ID: 20802015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
    Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
    Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
    Peintinger F; Anderson K; Mazouni C; Kuerer HM; Hatzis C; Lin F; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Jul; 13(14):4078-82. PubMed ID: 17634532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
    Rouzier R; Perou CM; Symmans WF; Ibrahim N; Cristofanilli M; Anderson K; Hess KR; Stec J; Ayers M; Wagner P; Morandi P; Fan C; Rabiul I; Ross JS; Hortobagyi GN; Pusztai L
    Clin Cancer Res; 2005 Aug; 11(16):5678-85. PubMed ID: 16115903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer.
    Ka NL; Na TY; Na H; Lee MH; Park HS; Hwang S; Kim IY; Seong JK; Lee MO
    Cancer Res; 2017 May; 77(9):2453-2463. PubMed ID: 28249904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.
    Weerts MJA; Hollestelle A; Sieuwerts AM; Foekens JA; Sleijfer S; Martens JWM
    Clin Cancer Res; 2017 Aug; 23(16):4735-4743. PubMed ID: 28420722
    [No Abstract]   [Full Text] [Related]  

  • 14. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
    Nielsen TO; Jensen MB; Burugu S; Gao D; Jørgensen CL; Balslev E; Ejlertsen B
    Clin Cancer Res; 2017 Feb; 23(4):946-953. PubMed ID: 27601592
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
    Klintman M; Buus R; Cheang MC; Sheri A; Smith IE; Dowsett M
    Clin Cancer Res; 2016 May; 22(10):2405-16. PubMed ID: 27179111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.